Patterns of statin use in a real-world population of patients at high cardiovascular risk

Journal of Managed Care and Specialty Pharmacy

Volumn 22, Issue 6, 2016, Pages 685-698

  Lin, Iris ^a   Sung, Jennifer ^b   Sanchez, Robert J ^c   Mallya, Usha G ^b   Friedman, Mark ^a   Panaccio, Mary ^b   Koren, Andrew ^b   Neumann, Peter ^d   Menzin, Joseph ^a  

^a Boston Health Economics   (United States)

^b SANOFI   (France)

^c REGENERON PHARMACEUTICALS INC   (United States)

^d TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RETROSPECTIVE STUDY; TREATMENT DURATION; ADOLESCENT; AGED; CARDIOVASCULAR DISEASES; HEALTH SURVEY; INSURANCE; MEDICATION COMPLIANCE; MIDDLE AGED; PROCEDURES; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSURANCE CLAIM REVIEW; MALE; MEDICATION ADHERENCE; MIDDLE AGED; POPULATION SURVEILLANCE; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84977524313     PISSN: 23760540     EISSN: 23761032     Source Type: Journal    
DOI: 10.18553/jmcp.2016.22.6.685     Document Type: Article

References (48)

1. Anderson TJ, Gregoire J, Hegele RA, et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2013;29(2):151-67.
2. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14):1769-818.
3. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889-934.
4. Teramoto T, Sasaki J, Ishibashi S, et al. Comprehensive risk management for the prevention of cardiovascular disease: executive summary of the Japan Atherosclerosis Society ( JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan-2012. J Atheroscler Thromb. 2013;20(7):603-15.
5. Gorcyca KM, Khan I, Wadhera R, et al. Prevalence of atherosclerotic cardiovascular disease and diabetes in the United States. Poster presented at: 2015 National Lipid Association Scientific Sessions; June 11-14, 2015; Chicago, IL. Available at: https://www.lipid.org/util/eposters/PDF/118.pdf. Accessed March 21, 2016.
6. Go AS, Mozaffarian D, Roger VL, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28-e292.
7. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123(8):933-44.
8. Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349-57.
9. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease:the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-89.
10. Sacks FM, Pfeffer MA, Moye LA, et al; Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335(14):1001-09.
11. Cannon CP, Braunwald E, McCabe CH, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495-504.
12. LaRosa JC, Grundy SM, Waters DD, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425-35.
13. Fu AZ, Zhang Q, Davies MJ, Pentakota SR, Radican L, Seck T. Underutilization of statins in patients with type 2 diabetes in US clinical practice: a retrospective cohort study. Curr Med Res Opin. 2011;27(5):1035-40.
14. Gamboa CM, Safford MM, Levitan EB, et al. Statin underuse and low prevalence of LDL-C control among U.S. adults at high risk of coronary heart disease. Am J Med Sci. 2014;348(2):108-14.
15. Hoeks SE, Scholteop Reimer WJ, van Gestel YR, et al. Medication underuse during long-term follow-up in patients with peripheral arterial disease. Circ Cardiovasc Qual Outcomes. 2009;2(4):338-43.
16. Subherwal S, Patel MR, Kober L, et al. Missed opportunities: despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains. Circulation. 2012;126(11):1345-54.
17. Kern DM, Balu S, Tunceli O, Anzalone D. Statin treatment patterns and clinical profile of patients with risk factors for coronary heart disease defined by National Cholesterol Education Program Adult Treatment Panel III. Curr Med Res Opin. 2014;30(12):2443-51.
18. Toth PP, Foody JM, Tomassini JE, et al. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease. J Clin Lipidol. 2014;8(1):107-16.
19. Melloni C, Shah BR, Ou FS, et al. Lipid-lowering intensification and low-density lipoprotein cholesterol achievement from hospital admission to 1-year follow-up after an acute coronary syndrome event: results from the Medications ApplIed aNd SusTAINed Over Time (MAINTAIN) registry. Am Heart J. 2010;160(6):1121-29.
20. Simpson RJ Jr, Tunceli K, Ramey DR, et al. Treatment pattern changes in high-risk patients newly initiated on statin monotherapy in a managed care setting. J Clin Lipidol. 2013;7(5):399-407.
21. Arnold SV, Spertus JA, Masoudi FA, et al. Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction. J Am Coll Cardiol. 2013;62(19):1791-801.
22. Arnold SV, Kosiborod M, Tang F, et al. Patterns of statin initiation, intensification, and maximization among patients hospitalized with an acute myocardial infarction. Circulation. 2014;129(12):1303-09.
23. Slejko JF, Ho M, Anderson HD, Nair KV, Sullivan PW, Campbell JD. Adherence to statins in primary prevention: yearly adherence changes and outcomes. J Manag Care Pharm. 2014;20(1):51-57. Available at: http://www. jmcp.org/doi/abs/10.18553/jmcp.2014.20.1.51.
24. Phan K, Gomez YH, Elbaz L, Daskalopoulou SS. Statin treatment nonadherence and discontinuation: clinical implications and potential solutions. Curr Pharm Des. 2014;20(40):6314-24.
25. Steen DL, Khan I, Song X, et al. Cardiovascular event rates in a highrisk managed care population in the United States. J Am Coll Cardiol. 2015;65(10):A1647. [Abstract]
26. Centers for Disease Control and Prevention/National Center for Health Statistics. Classifications of disease, functioning, and disability. Updated June 19, 2013. Available at: http://www.cdc.gov/nchs/icd.htm. Accessed March 21, 2016.
27. Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15(9):728-40. Available at: http://www.amcp.org/data/jmcp/728-740.pdf.
28. Zullig LL, Melnyk SD, Stechuchak KM, et al. The Cardiovascular Intervention Improvement Telemedicine Study (CITIES): rationale for a tailored behavioral and educational pharmacist-administered intervention for achieving cardiovascular disease risk reduction. Telemed J E Health. 2014;20(2):135-43.
29. Fung V, Sinclair F, Wang H, Dailey D, Hsu J, Shaber R. Patients' perspectives on nonadherence to statin therapy: a focus-group study. Perm J. 2010;14(1):4-10.
30. McNaughton RJ, Shucksmith J. Reasons for (non)compliance with intervention following identification of "high-risk" status in the NHS Health Check programme. J Public Health (Oxf). 2015;37(2):218-25.
31. Pedan A, Varasteh L, Schneeweiss S. Analysis of factors associated with statin adherence in a hierarchical model considering physician, pharmacy, patient, and prescription characteristics. J Manag Care Pharm. 2007;13(6):487-96. Available at: http://www.amcp.org/data/jmcp/pages%20487-96.pdf.
32. Virani SS, Woodard LD, Akeroyd JM, Ramsey DJ, Ballantyne CM, Petersen LA. Is high-intensity statin therapy associated with lower statin adherence compared with low- to moderate-intensity statin therapy? Implications of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guidelines. Clin Cardiol. 2014;37(11):653-59.
33. Watanabe JH, Kazerooni R, Bounthavong M. Association of copayment with likelihood and level of adherence in new users of statins: a retrospective cohort study. J Manag Care Pharm. 2014;20(1):43-50. Available at: http:// www.jmcp.org/doi/abs/10.18553/jmcp.2014.20.1.43.
34. Chen S-Y, Shah S-N, Lee YC, Boulanger L, Mardekian J, Kuznik A. Moving branded statins to lowest copay tier improves patient adherence. J Manag Care Pharm. 2014;20(1):34-42. Available at: http://www.jmcp.org/ doi/abs/10.18553/jmcp.2014.20.1.34.
35. Caspard H, Chan AK, Walker AM. Compliance with a statin treatment in a usual-care setting: retrospective database analysis over 3 years after treatment initiation in health maintenance organization enrollees with dyslipidemia. Clin Ther. 2005;27(10):1639-46.
36. Tziomalos K, Athyros VG, Mikhailidis DP. Statin discontinuation: an underestimated risk? Curr Med Res Opin. 2008;24(11):3059-62.
37. Gomez Sandoval YH, Braganza MV, Daskalopoulou SS. Statin discontinuation in high-risk patients: a systematic review of the evidence. Curr Pharm Des. 2011;17(33):3669-89.
38. Mancini GB, Baker S, Bergeron J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. Can J Cardiol. 2011;27(5):635-62.
39. Robinson JG. Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Manag Care Pharm. 2013;19(2):139-49. Available at: http://www.jmcp.org/doi/abs/10.18553/jmcp.2013.19.2.139.
40. Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6(3):208-15.
41. Wei MY, Ito MK, Cohen JD, Brinton EA, Jacobson TA. Predictors of statin adherence, switching, and discontinuation in the USAGE survey:understanding the use of statins in America and gaps in patient education. J Clin Lipidol. 2013;7(5):472-83.
42. Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: population based study. BMJ. 2013;346:f2610.
43. Dormuth CR, Filion KB, Paterson JM, et al. Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases. BMJ. 2014;348:g3244.
44. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305(24):2556-64.
45. Dormuth CR, Hemmelgarn BR, Paterson JM, et al. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases. BMJ. 2013;346:f880.
46. Corrao G, Soranna D, Casula M, Merlino L, Porcellini MG, Catapano AL. High-potency statins increase the risk of acute kidney injury: evidence from a large population-based study. Atherosclerosis. 2014;234(1):224-29.
47. U.S. Food and Drug Administration. Limit use of 80 mg simvastatin. Consumer Health Information. June 8, 2011. Available at: http://www.fda.gov/ ForConsumers/ConsumerUpdates/ucm257884.htm. Accessed March 21, 2016.
48. Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1-full report. J Clin Lipidol. 2015;9(2):129-69.